Overview

Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura

Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The following study is being conducted to explore the safety and effectiveness of a new chemical entity called NXN-188 in subjects with a history of migraine with aura. In this study subjects will treat two attacks of migraine with aura during the aura phase - once with placebo and once with NXN-188.
Phase:
Phase 2
Details
Lead Sponsor:
Danish Headache Center
Collaborator:
NeurAxon Inc.